nclude a $34,000 reduction in clinical study fees and a $66,000 reduction in consultant and professional fees. Clinical study fees decreased as the Gout trial concluded in April 2012 and fees were incurred on 13 completed patients. In 2011 clinical study fees were higher due to costs related to conducting a non-human primate toxicology study. Consulting and professional fees have decreased as the Company filed the IND for the Gout trial in 2011 while in 2012 there were normal expenses in this area.
General and administrative expenses for the second quarter of 2012 decreased by $21,664, or 8%, from $259,415 in 2011 to $237,751 in 2012. The primary reductions were a $7,000 reduction in salaries and benefits and a $15,000 reduction in various other areas. The decrease in payroll costs in 2012 reflects lower stock compensation. There was also a reduction of various facility related expenses as the Company continued to reduce and manage overhead.
Six-months Ended June 30, 2012For the six months ended June 30, 2012, Pharmos recorded a net loss of $1.0 million, or ($0.02) per share compared to a net loss of $1.1 million, or ($0.02) per share for the six months ended June 30, 2011.
Research & development expenses for the first half of 2012 decreased by $90,733, or 18%, from $496,254 in 2011 to $405,521 in 2012. The primary areas include an $115,000 increase in clinical study fees which were offset by a $204,000 reduction in consultant and professional fees and a $2,000 reduction in various other areas. Clinical study fees increased as the Gout trial commenced in January 2012 and fees were incurred on 13 completed patients. Consulting and professional fees have decreased as the Company filed the IND for the Gout trial in 2011 while in 2012 there were normal expenses in this area.
General and administrative expenses for the first half of 2012 decreased by $55,952, or 10%, from $553,760 in 2011 to $497,808 in 2012. The primary redPage: 1 2 3 4 Related biology technology :1
. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results2
. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility3
. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 20124
. Neogen Corporation Announces Year-End Results Conference Call5
. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego6
. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year7
. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair8
. China Cord Blood Corporation Continues Share Repurchase Program9
. Triple-S Management Corporation Announces the Retirement of Socorro Rivas-Rodriguez; Names Pablo Almodovar Scalley as Successor10
. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart11
. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials